<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="1645">
  <stage>Registered</stage>
  <submitdate>8/08/2007</submitdate>
  <approvaldate>8/08/2007</approvaldate>
  <nctid>NCT00514527</nctid>
  <trial_identification>
    <studytitle>A Study for Patients With Complicated Skin and Skin Structure Infections</studytitle>
    <scientifictitle>NuvocidÂ® (Oritavancin) at Single or Infrequent Doses for the Treatment of Complicated Skin and Skin Structure Infections (SIMPLIFI)</scientifictitle>
    <utrn />
    <trialacronym>SIMPLIFI</trialacronym>
    <secondaryid>TAR-ORI-SD001</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Staphylococcal Skin Infections</healthcondition>
    <healthcondition>Wounds and Injuries</healthcondition>
    <healthcondition>Abscess</healthcondition>
    <healthcondition>Cellulitis</healthcondition>
    <healthcondition>Streptococcal Infections</healthcondition>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Studies of infection and infectious agents</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Other infectious diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Sexually transmitted infections</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Skin</conditioncode1>
      <conditioncode2>Other skin conditions</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - oritavancin

Experimental: 1 - 

Experimental: 2 - 

Experimental: 3 - 


Treatment: drugs: oritavancin
Oritavancin as a single, infrequent or daily dose.

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Clinical success at follow-up</outcome>
      <timepoint>six months</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>To evaluate safety of dosing regimens.</outcome>
      <timepoint>six months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Inclusion Criteria

          -  Complicated skin and skin structure infection, presumed or proven to be caused by
             gram-positive pathogen(s).

          -  Patients, ages 18 years and older, must not be below normal body weight or morbidly
             obese.

          -  Female patients must not be pregnant at time of enrollment and must agree to a
             reliable method of birth control during the study and for 6 months following the last
             dose of study drug.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Patients:

          -  with a condition which would prevent performing protocol safety and efficacy
             assessments.

          -  who have received antibiotics for more than 24 hours within the last 3 days.

          -  with an infection involving deep tissues or unlikely to be caused by gram positive
             bacteria

          -  who are nursing and will not stop nursing for at least 6 months

          -  with a prior allergic reaction to glycopeptides (e.g. vancomycin)

          -  with any of the following:

               1. toxic shock syndrome or toxic-like syndrome

               2. presumed or proven infection caused by Clostridium species

               3. bone infections

               4. ischemic or gangrenous ulcers or wounds

               5. infections caused only by gram-negative bacteria

               6. infection of an artificial joint that cannot be removed

               7. infection of the scrotum, perineum or perianal region

               8. infection of a severe burn wound

               9. severe ear infection involving bone and/or cartilage

              10. infection following injury in water possibly containing Vibrio species or
                  following a history of eating raw oysters within 1 week prior to disease onset</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3>The people assessing the outcomes</masking3>
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/08/2007</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>294</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/05/2008</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>QLD,VIC</recruitmentstate>
    <hospital>Targanta Recruiting Site - Cairns</hospital>
    <hospital>Targanta Recruiting Site - Nambour</hospital>
    <hospital>Targanta Recruiting Site - Woolloongabba</hospital>
    <hospital>Targanta Recruiting Site - East Ringwood</hospital>
    <hospital>Targanta Recruiting Site - Parkville</hospital>
    <hospital>Targanta Recruiting Site - Fremantle</hospital>
    <postcode>4870 - Cairns</postcode>
    <postcode>4560 - Nambour</postcode>
    <postcode>4102 - Woolloongabba</postcode>
    <postcode>3135 - East Ringwood</postcode>
    <postcode>3050 - Parkville</postcode>
    <postcode>6160 - Fremantle</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Alabama</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Georgia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Indiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Louisiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Maryland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Michigan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Minnesota</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Ohio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Tennessee</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Utah</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>Andhra Pradesh</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>Gujarat</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>Karnataka</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>Kerala</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>Maharashtra</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>Uttar Pradesh</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Catania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Mantova</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Milano</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Pisa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Savona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Siena</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Romania</country>
      <state>Bucharest</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Romania</country>
      <state>Craiova</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ukraine</country>
      <state>Ivano-frankovsk</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ukraine</country>
      <state>Kharkov</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ukraine</country>
      <state>Kiev</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ukraine</country>
      <state>Odessa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ukraine</country>
      <state>Ternopil</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ukraine</country>
      <state>Zaporizhzhya</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Targanta Therapeutics Corporation</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>Two Phase III trials to demonstrate the efficacy and safety of oritavancin in the treatment
      of complicated skin and skin structure infections (cSSSI) have been completed.

      The pharmacokinetic profile of oritavancin in humans suggests that oritavancin has the
      potential to be used safely and effectively when given either as a single dose or as an
      infrequent dose for cSSSI. Data from animals support this theory.

      SIMPLIFI has been designed to evaluate the efficacy and safety of either a single dose of
      oritavancin or an infrequent dose of oritavancin (First dose on Day one with an option for a
      second dose on Day five) compared to the previously studied dosing regimen of 200mg
      oritavancin given once daily for 3 to 7 days.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00514527</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Targanta Therapeutics</name>
      <address>simplifi@covance.com</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>